MBM Wealth Consultants’s Jazz Pharmaceuticals JAZZ Stock Holding History

MBM Wealth Consultants’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10	Closed	-$1K	–	191
2023 Q1	$1K	Hold	10	–	–	﹤0.01%	264
2022 Q4	$2K	Hold	10	–	–	﹤0.01%	309
2022 Q3	$1K	Hold	10	–	–	﹤0.01%	258
2022 Q2	$2K	Hold	10	–	–	﹤0.01%	252
2022 Q1	$2K	Hold	10	–	–	﹤0.01%	283
2021 Q4	$1K	Hold	10	–	–	﹤0.01%	281
2021 Q3	$1K	Buy	+10	New	+$1.51K	﹤0.01%	277

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

MBM Wealth Consultants's JAZZ Position: Q2 2023 in Review

MBM Wealth Consultants sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 10 shares — an estimated $1K sold.

MBM Wealth Consultants first reported a position in JAZZ in Q3 2021 and held it in 7 quarters. The position peaked at $2K in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

MBM Wealth Consultants reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
MBM Wealth Consultants sold 10 Jazz Pharmaceuticals shares in Q2 2023, an estimated $1K.
MBM Wealth Consultants first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 7 quarters.
MBM Wealth Consultants's Jazz Pharmaceuticals position peaked at $2K in Q4 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on MBM Wealth Consultants's 13F filing for Q2 2023, filed 24 Jul 2023.